Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2013) 1 PP396 | DOI: 10.1530/boneabs.1.PP396

ECTS2013 Poster Presentations Osteoporosis: treatment (64 abstracts)

Characterization and risk factors of acute-phase response following a first-dose administration of zoledronic acid for treatment of osteoporosis

Decai Chen


West China Hospital, Sichuan University, Chengdu, China.


Objective: To explore the characterization and risk factors of acute-phase response (APR) following a first-dose administration of 5 mg zoledronic acid for treatment of osteoporosis.

Method: We conducted clinical data of the zoledronic acid users for treatment of osteoporosis in Department of Endocrinology, West China Hospital, Sichuan University from January 2009 to November 2012.

Results: A total of 178 patients were eligible for inclusion in the study, of which 108 patients has experienced the APR. 80 (45%)patients developed fever, 14 (9.6%) chills, 48 (27%) musculoskeletal pain, 19 (10.7%) gastrointestinal symptoms, 10 (5.6%)headache and dizziness, 7 (3.9%)palpitation,and 3 (1.7%) rash. APR was more common in patients with higher baseline tartrate-resistant acid phosphatase 5b (TRACP-5b) and new-onset vertebral compression fractures (new-onset VCF). Stepwise logistic regression showed that the odds ratio (OR) to have APR in higher baseline TRACP-5b and new VCF was 3.3 and 2.5 respectively.

Conclusion: Patients with higher baseline TRACP-5b and new-onset VCF are more frequency in development of APR, which is worth to pay more attention to these patients.

Key words: Zoledronic acid, Acute-phase response, Osteoporosis.

Volume 1

European Calcified Tissue Society Congress 2013

Lisbon, Portugal
18 May 2013 - 22 May 2013

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.